Tomoyuki Suzuki1, Yuriko Saiki2, Akira Horii2, Shinichi Fukushige2, Shunsuke Kawamoto1, Osamu Adachi1, Masatoshi Akiyama1, Koki Ito1, Naoki Masaki1, Yoshikatsu Saiki3. 1. Division of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryocho, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. 2. Department of Molecular Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryocho, Aoba-ku, Sendai, Miyagi, 980-8575, Japan. 3. Division of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryocho, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. yoshisaiki@med.tohoku.ac.jp.
Abstract
OBJECTIVES: Atrial natriuretic peptide is a cardiac atrium-derived hormone and its cardioprotective effects have recently been confirmed, but the actual mechanism underlying these effects has not been well elucidated. In this study, we proposed that atrial natriuretic peptide achieves its effects in part via peroxisome proliferator activated receptor γ, a nuclear receptor. METHODS: Hemodynamic data in swine heart ischemia-reperfusion model were measured under the conditions of no medication for control (Group N, n = 8) or that of carperitide (synthetic human atrial natriuretic peptide) systemic administration (Group A, n = 8). After 30 min of left anterior descending artery total occlusion and 4 h of reperfusion, peroxisome proliferator activated receptor γ mRNA and protein expressions in cardiac muscle were examined. The mRNA expression of Liver X receptor α, the downstream agent of peroxisome proliferator activated receptor γ, was also evaluated. Creatine kinase-myocardial band and Troponin T elevations after reperfusion were evaluated as markers of cardiac damage. RESULTS: The dP/dT decrease during reperfusion was ameliorated in Group A. Peroxisome proliferator activated receptor γ mRNA expression in Group A was significantly higher in ischemic area than that in Group N, although the difference was not significant in the marginal and non-ischemic areas. The peroxisome proliferator activated receptor γ protein expression in ischemic area was also significantly dominant in Group A. CONCLUSIONS: Atrial natriuretic peptide may achieve its cardioprotective effects in part via the activation of the peroxisome proliferator activated receptor γ pathway, particularly in central areas of ischemic lesions.
OBJECTIVES: Atrial natriuretic peptide is a cardiac atrium-derived hormone and its cardioprotective effects have recently been confirmed, but the actual mechanism underlying these effects has not been well elucidated. In this study, we proposed that atrial natriuretic peptide achieves its effects in part via peroxisome proliferator activated receptor γ, a nuclear receptor. METHODS: Hemodynamic data in swine heart ischemia-reperfusion model were measured under the conditions of no medication for control (Group N, n = 8) or that of carperitide (synthetic human atrial natriuretic peptide) systemic administration (Group A, n = 8). After 30 min of left anterior descending artery total occlusion and 4 h of reperfusion, peroxisome proliferator activated receptor γ mRNA and protein expressions in cardiac muscle were examined. The mRNA expression of Liver X receptor α, the downstream agent of peroxisome proliferator activated receptor γ, was also evaluated. Creatine kinase-myocardial band and Troponin T elevations after reperfusion were evaluated as markers of cardiac damage. RESULTS: The dP/dT decrease during reperfusion was ameliorated in Group A. Peroxisome proliferator activated receptor γ mRNA expression in Group A was significantly higher in ischemic area than that in Group N, although the difference was not significant in the marginal and non-ischemic areas. The peroxisome proliferator activated receptor γ protein expression in ischemic area was also significantly dominant in Group A. CONCLUSIONS: Atrial natriuretic peptide may achieve its cardioprotective effects in part via the activation of the peroxisome proliferator activated receptor γ pathway, particularly in central areas of ischemic lesions.
Authors: Nina Schlueter; Anita de Sterke; Diana M Willmes; Joachim Spranger; Jens Jordan; Andreas L Birkenfeld Journal: Pharmacol Ther Date: 2014-04-27 Impact factor: 12.310
Authors: Martina I Lefterova; Anders K Haakonsson; Mitchell A Lazar; Susanne Mandrup Journal: Trends Endocrinol Metab Date: 2014-04-29 Impact factor: 12.015
Authors: A Chawla; W A Boisvert; C H Lee; B A Laffitte; Y Barak; S B Joseph; D Liao; L Nagy; P A Edwards; L K Curtiss; R M Evans; P Tontonoz Journal: Mol Cell Date: 2001-01 Impact factor: 17.970